INTRODUCTION {#s1}
============

High altitude pulmonary edema (HAPE) is a non-cardiogenic form of pulmonary edema that develops in unacclimatized healthy individuals at altitudes above 2500--3000 m \[[@R1]\]. It is a potentially fatal medical condition and the most common cause of death among high-altitude illnesses \[[@R2]\]. However, the pathogenesis of HAPE remains poorly understood. Previous studies suggest that uneven hypoxic pulmonary vasoconstriction, pulmonary capillary damage, and increased pulmonary artery pressure play important roles in the pathogenesis of HAPE \[[@R3], [@R4]\].

HAPE is caused by the interaction of both genetic and environmental risk factors. Previous studies have shown that family history and race influence individual susceptibilities to HAPE \[[@R5]\]. Some people are susceptible to high-altitude pulmonary edema, whereas others are resistant to this condition \[[@R6], [@R7]\]. The prevalence of HAPE in the Han Chinese population in Tibet, which is about 0.4%\~2% \[[@R8]\] and differs depending on age, gender, and occupation, is higher than that observed in native Tibetans. Rate of ascent, altitude reached, pre-acclimatization, and individual susceptibility are the major factors that contribute to high-altitude maladies \[[@R9]\]. In addition, patients who have previously developed HAPE are more likely to experience recurrence, which suggests the presence of a constitutional, and possibly a genetic, component in its etiology \[[@R10]\].

Several recent studies have examined the genetic basis of HAPE, focusing mainly on genetic polymorphisms in the beta2-adrenergic receptor \[[@R11]\], vascular endothelial growth factor \[[@R12]\], the renin angiotensin system \[[@R13]\], and pulmonary surfactant proteins A1 and A2 \[[@R14]\] in subjects susceptible to HAPE. Polymorphisms within these genes may explain individual variation in hypoxic responses and perhaps indicate susceptibility to high-altitude disease. However, the precise role of these genes in HAPE pathogenesis remains unclear.

To identify genetic variants across the whole genome that are specifically related to HAPE risk, we conducted a two-stage GWAS analysis in 68 patients with recurrent HAPE and in 84 HapMap CHB populations as references. We further evaluated potential associations with HAPE risk in a replication cohort with a total of 199 HAPE patients and 304 healthy controls from a Han Chinese population. While previous GWAS studies were based on case-control samples only, here we examined a large number of cases to identify genes that might be related to HAPE susceptibility.

RESULTS {#s2}
=======

A total of 571 subjects, including 267 HAPE patients (246 males, 21 females; mean age 32.6 ± 10.7) and 304 controls (290 males, 14 females; mean age 36.2 ± 4.5), were examined in this analysis. Age distribution differed between the patient and control groups (*p* \< 0.05). Participant characteristics are listed in Table [1](#T1){ref-type="table"}.

###### Basic characteristics of cases and controls in this study

  Variables     Case N (%)    Control N (%)   *p*-value
  ------------- ------------- --------------- -------------
  Age (years)   32.6 ± 10.7   36.2 ± 4.5      \< 0.005^a^
  Sex                                         \> 0.005^b^
  Male          246 (92.0%)   290 (95.4%      
  Female        21 (8.0%)     14 (4.6%)       
  Total         267           304             

^a^*P* values were calculated from two-sided chi-square tests.

^b^*P* values were calculated by Student *t* tests.

We first scanned DNA samples from 68 patients with recurrent HAPE using Affymetrix Genome-Wide Human SNP Array 6.0 Chips. After filtering with standard quality-control procedures, 502,689 SNPs with an overall call rate of 99.92% were qualified for further GWAS analysis. To identify SNPs that might be associated with the risk of HAPE, we compared SNP allele frequencies in the 68 patients to those of the 84 HapMap CHB controls and found that frequencies differed for 77 SNPs. Information regarding these 77 SNPs and their associated genes is shown in Table [2](#T2){ref-type="table"}. A Manhattan plot was generated for the SNPs in patients with recurrent HAPE under the allelic and genotypic model (Figure [1](#F1){ref-type="fig"}). MDS and QQ-plot revealed that there was no obvious population stratification in this experiment (Figure [2](#F2){ref-type="fig"} and Figure [3](#F3){ref-type="fig"}).

###### Basic information of the significantly different SNPs between 68 recurrent HAPE cases and 84 Hapmap CHB subjects in the first stage

  SNP ID       Chromosome   Gene (s)   Alleles   MAF     Position   Band        Role       
  ------------ ------------ ---------- --------- ------- ---------- ----------- ---------- -------------------
  rs4908427    1            CAMTA1     G/A       0.059   0.054      6976226     1p36.31    Intron
  rs9661274    1                       G/A       0.059   0.060      30149249    1p35.3     
  rs17484974   1                       C/T       0.132   0.054      39186794    1p34.3     
  rs12406517   1            PPAP2B     G/C       0.110   0.072      56974278    1p32.2     Intron
  rs1694212    1                       T/C       0.132   0.113      61480000    1p31.3     
  rs10789097   1                       C/G       0.066   0.071      62119978    1p31.3     
  rs17188846   1            KCNH1      C/G       0.184   0.067      211261821   1q32.2     Intron
  rs2577156    1            EPRS       C/A       0.051   0.077      220190845   1q41       Intron
  rs3008613    1            MIA3       G/A       0.110   0.079      222795769   1q41       Intron
  rs4491711    2            RASGRP3    G/A       0.103   0.066      33776743    2p22.3     Intron
  rs11125567   2            CCDC88A    A/G       0.081   0.143      55627913    2p16.1     Intron
  rs11898268   2                       C/A       0.000   0.071      154622125   2q23.3     
  rs10167840   2                       T/G       0.140   0.077      199241493   2q33.1     
  rs7612512    3                       G/C       0.140   0.157      3412838     3p26.2     
  rs1846594    3                       C/T       0.213   0.196      112916203   3q13.2     
  rs11924340   3                       A/G       0.060   0.110      145325196   3q24       
  rs12504325   4            C4orf6     A/G       0.103   0.083      5537184     4p16.2     Downstream
  rs17598758   4                       G/T       0.110   0.089      20190068    4p15.31    
  rs7677143    4                       C/T       0.147   0.220      117082198   4q26       
  rs6535838    4                       A/C       0.199   0.101      153023402   4q31.3     
  rs7688505    4                       T/A       0.110   0.110      185828318   4q35.1     
  rs41417552   5            CMBL       G/A       0.110   0.083      10305452    5p15.2     Intron
  rs2161592    5                       A/G       0.162   0.085      50772554    5q11.2     
  rs3777207    5            ELL2       A/G       0.118   0.084      95231115    5q15       Intron
  rs6595114    5                       C/T       0.118   0.101      117676709   5q23.1     
  rs2193963    5                       C/T       0.096   0.089      121596196   5q23.2     
  rs17652561   5            SLC6A7     A/G       0.162   0.185      149584197   5q32       Intron (boundary)
  rs2937582    5                       A/G       0.434   0.080      166465008   5q34       
  rs2984100    6                       C/G       0.125   0.143      8592499     6p24.3     
  rs7762263    6                       T/C       0.110   0.066      11975250    6p24.1     
  rs4715938    6                       G/C       0.103   0.113      14944857    6p23       
  rs725050     6                       C/T       0.162   0.196      89267376    6q15       
  rs1419722    7            EIF3B      C/T       0.142   0.107      2413258     7p22.3     Intron
  rs10178082   7                       T/A       0.199   0.157      10706912    7p21.3     
  rs4947936    7                       C/A       0.103   0.133      50906752    7p12.1     
  rs12226072   7                       A/T       0.294   0.339      96443614    7q21.3     
  rs2956956    8            DLGAP2     C/T       0.066   0.083      1553118     8p23.3     Intron
  rs2980508    8            SGK223     C/T       0.096   0.106      8171732     8p23.1     Downstream
  rs310282     8                       C/A       0.132   0.125      23614369    8p21.2     
  rs4573320    8                       C/T       0.343   0.446      65128758    8q12.3     
  rs1568828    8            PREX2      A/G       0.081   0.101      69122128    8q13.2     Intron
  rs1006698    9            KCNV2      T/G       0.206   0.232      2725283     9p24.2     Intron
  rs1011531    9                       A/G       0.110   0.114      13755192    9p23       
  rs13289064   9                       C/G       0.228   0.179      16897685    9p22.2     
  rs10984811   9            ANP32B     C/A       0.149   0.173      100784050   9q22.33    Downstream
  rs12554842   9            COL5A1     T/C       0.081   0.071      137573407   9q34.3     Intron
  rs11593009   10                      T/A       0.051   0.065      31974946    10p11.22   
  rs12243354   10           TET1       A/G       0.125   0.131      70411536    10q21.3    Intron (boundary)
  rs7923700    10           GRID1      G/A       0.162   0.190      87843290    10q23.1    Intron
  rs2239153    12           VWF        C/T       0.338   0.399      6186667     12p13.31   Intron
  rs7303062    12                      A/G       0.074   0.084      22990450    12p12.1    
  rs10879780   12                      T/G       0.235   0.226      74837984    12q21.1    
  rs1316571    13                      T/C       0.081   0.095      68320718    13q21.32   
  rs9550256    13           FAM70B     A/T       0.265   0.220      114494675   13q34      Intron
  rs17435983   14                      A/G       0.169   0.101      27860597    14q12      
  rs8007744    14                      G/A       0.265   0.262      28329396    14q12      
  rs17777329   14                      G/A       0.081   0.060      101934762   14q32.31   
  rs4787426    16           IL4R       G/T       0.059   0.065      27384731    16p12.1    Downstream
  rs1075355    16           VAT1L      C/G       0.147   0.107      77874149    16q23.1    Intron
  rs12931468   16           ATP2C2     G/C       0.074   0.054      84495301    16q24.1    Intron (boundary)
  rs8067836    17           LASP1      G/T       0.081   0.071      37081707    17q12      Downstream
  rs16955841   17           HLF        G/A       0.105   0.107      53364146    17q22      Intron
  rs12450240   17           NARF       T/G       0.265   0.235      80423712    17q25.3    Intron
  rs9961715    18           DLGAP1     C/T       0.029   0.054      3824312     18p11.31   Intron
  rs12606093   18           KIAA0427   C/A       0.044   0.065      46077295    18q21.1    Intron
  rs6074799    20           MACROD2    G/C       0.110   0.101      14771472    20p12.1    Intron
  rs9617661    22           TUBA8      G/T       0.029   0.060      18595352    22q11.21   Intron
  rs5758913    22                      C/T       0.154   0.161      43148259    22q13.2    

Notes: A/B stands for minor/major alleles on the entire sample frequencies.

![Manhattan plot for the whole SNPs in recurrent HAPE subjects of Chinese Han decent\
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Of the 77 SNPs, 68 were qualified after Sequenom MassARRAY Assay Design. In a second experiment, we confirmed the results of the first experiment by genotyping the 68 SNPs in 199 HAPE patients and 304 controls of Han Chinese descent. Table [3](#T3){ref-type="table"} summarizes the characteristics of the tested SNPs and their predicted associations with HAPE risk in crude analysis. Three SNPs (rs17484974, rs725050, and rs10178082) were excluded at the 5% *p-value* for Hardy-Weinberg equilibrium (HWE). A χ^2^ test revealed that two SNPs, rs10789097 (OR = 1.825; 95% CI= 1.062--3.135, *p* = 0.027), and rs17777329 (OR = 1.800; 95% CI = 1.083--2.991, *p* = 0.022) were associated with an increased risk of HAPE (Table [3](#T3){ref-type="table"}).

###### Allele frequencies in cases and controls and odds ratio estimates for HAPE for the replication stage

  SNP ID       Gene (s)   Alleles   MAF     HWE     ORs             95% CI   *p*-value           
  ------------ ---------- --------- ------- ------- --------------- -------- ----------- ------- ---------
  rs4908427    CAMTA1     G/A       0.035   0.048   1               0.728    0.380       1.395   0.337
  rs9661274               G/A       0.065   0.067   0.3787          0.967    0.581       1.607   0.896
  rs17484974              C/T       0.111   0.112   7.851E-47^\#^   0.987    0.660       1.476   0.949
  rs12406517   PPAP2B     G/C       0.055   0.054   0.2131          1.020    0.585       1.776   0.946
  rs1694212               T/C       0.139   0.133   0.8025          1.049    0.726       1.517   0.798
  rs10789097              C/G       0.075   0.043   1               1.825    1.062       3.135   0.027\*
  rs17188846   KCNH1      C/G       0.139   0.130   0.198           1.080    0.746       1.564   0.683
  rs2577156    EPRS       C/A       0.076   0.077   0.08963         0.978    0.607       1.576   0.928
  rs3008613    MIA3       G/A       0.093   0.105   0.552           0.871    0.569       1.334   0.526
  rs4491711    RASGRP3    G/A       0.063   0.097   1               0.624    0.384       1.014   0.055
  rs11125567   CCDC88A    A/G       0.111   0.127   1               0.857    0.578       1.271   0.443
  rs11898268              C/A       0.003   0.000   1               \-       \-          \-      \-
  rs10167840              T/G       0.088   0.095   1               0.914    0.589       1.420   0.690
  rs7612512               G/C       0.151   0.172   1               0.857    0.606       1.212   0.382
  rs1846594               C/T       0.193   0.232   0.6287          0.794    0.582       1.085   0.148
  rs11924340              A/G       0.111   0.086   0.4683          1.329    0.871       2.029   0.186
  rs12504325   C4orf6     A/G       0.083   0.090   0.4886          0.909    0.579       1.428   0.679
  rs17598758              G/T       0.101   0.105   1               0.950    0.626       1.441   0.808
  rs7677143               C/T       0.143   0.191   1               0.709    0.502       1.002   0.051
  rs6535838               A/C       0.133   0.137   0.4691          0.972    0.671       1.407   0.879
  rs7688505               T/A       0.156   0.140   0.8133          1.135    0.796       1.619   0.483
  rs41417552   CMBL       G/A       0.169   0.127   0.4419          1.404    0.985       2.003   0.060
  rs2161592               A/G       0.108   0.102   0.7525          1.067    0.707       1.609   0.758
  rs3777207    ELL2       A/G       0.108   0.107   0.5511          1.012    0.673       1.521   0.955
  rs6595114               C/T       0.118   0.097   0.5042          1.246    0.830       1.870   0.288
  rs2193963               C/T       0.106   0.095   1               1.130    0.742       1.721   0.568
  rs17652561   SLC6A7     A/G       0.145   0.151   0.6541          0.949    0.663       1.357   0.773
  rs2937582               A/G       0.439   0.434   0.6413          1.021    0.791       1.318   0.871
  rs2984100               C/G       0.184   0.156   0.2747          1.220    0.873       1.707   0.244
  rs7762263               T/C       0.111   0.123   0.594           0.883    0.595       1.312   0.539
  rs4715938               G/C       0.161   0.155   0.3873          1.048    0.741       1.481   0.792
  rs725050                C/T       0.249   0.243   0.04164^\#^     1.029    0.767       1.381   0.849
  rs1419722    EIF3B      C/T       0.143   0.149   0.648           0.958    0.669       1.372   0.816
  rs10178082              T/A       0.141   0.161   0.0001595^\#^   0.852    0.597       1.216   0.378
  rs4947936               C/A       0.163   0.150   0.6502          1.109    0.784       1.569   0.559
  rs12226072              A/T       0.317   0.340   0.7994          0.897    0.685       1.175   0.431
  rs2956956    DLGAP2     C/T       0.078   0.092   0.7288          0.833    0.527       1.317   0.433
  rs2980508    SGK223     C/T       0.146   0.135   1               1.097    0.763       1.576   0.619
  rs310282                C/A       0.096   0.135   0.3231          0.678    0.451       1.019   0.061
  rs4573320               C/T       0.279   0.299   0.8912          0.907    0.685       1.200   0.493
  rs1568828    PREX2      A/G       0.108   0.109   0.3729          0.995    0.662       1.494   0.980
  rs1006698    KCNV2      T/G       0.216   0.263   0.2387          0.772    0.572       1.041   0.089
  rs1011531               A/G       0.118   0.120   1               0.981    0.664       1.450   0.925
  rs13289064              C/G       0.231   0.183   1               1.346    0.986       1.837   0.060
  rs10984811   ANP32B     C/A       0.178   0.148   0.6479          1.250    0.889       1.757   0.199
  rs12554842   COL5A1     T/C       0.095   0.109   0.2273          0.867    0.569       1.320   0.505
  rs11593009              T/A       0.078   0.076   0.6833          1.032    0.642       1.658   0.896
  rs12243354   TET1       A/G       0.138   0.137   0.809           1.014    0.703       1.464   0.940
  rs7923700    GRID1      G/A       0.116   0.117   0.399           0.988    0.666       1.467   0.954
  rs2239153    VWF        C/T       0.415   0.428   0.4145          0.948    0.734       1.224   0.682
  rs7303062               A/G       0.050   0.061   0.6129          0.817    0.467       1.428   0.477
  rs10879780              T/G       0.193   0.192   0.5762          1.007    0.731       1.389   0.964
  rs1316571               T/C       0.078   0.079   0.102           0.985    0.616       1.577   0.951
  rs9550256    FAM70B     A/T       0.234   0.261   0.232           0.865    0.644       1.161   0.333
  rs17435983              A/G       0.143   0.128   0.7988          1.136    0.786       1.640   0.497
  rs8007744               G/A       0.261   0.267   0.7692          0.973    0.729       1.299   0.852
  rs17777329              G/A       0.085   0.049   0.5287          1.800    1.083       2.991   0.022\*
  rs4787426    IL4R       G/T       0.083   0.066   1               1.284    0.795       2.073   0.306
  rs1075355    VAT1L      C/G       0.131   0.092   0.1553          1.481    0.992       2.212   0.053
  rs12931468   ATP2C2     G/C       0.055   0.044   1               1.259    0.707       2.244   0.434
  rs8067836    LASP1      G/T       0.111   0.082   0.7057          1.387    0.906       2.125   0.131
  rs16955841   HLF        G/A       0.133   0.109   0.1143          1.255    0.830       1.898   0.282
  rs12450240   NARF       T/G       0.242   0.281   0.8872          0.818    0.612       1.093   0.174
  rs9961715    DLGAP1     C/T       0.055   0.041   0.4021          1.364    0.758       2.455   0.298
  rs12606093   KIAA0427   C/A       0.063   0.066   0.3739          0.952    0.568       1.595   0.851
  rs6074799    MACROD2    G/C       0.113   0.140   0.2313          0.784    0.533       1.154   0.216
  rs9617661    TUBA8      G/T       0.050   0.033   1               1.556    0.826       2.930   0.168
  rs5758913               C/T       0.156   0.151   0.6541          1.035    0.729       1.469   0.848

Notes: a Minor allele; \**p* value ≤ 0.05 indicates statistical significance; ^\#^site with HWE *p* ≤ 0.05 is excluded;

Abbreviations: HWE, Hardy-Weinberg Equilibrium; MAF, minor allele frequency; SNP, single nucleotide polymorphism; ORs, odds ratios; CI, confidence interval.

Associations between the SNPs and HAPE risk were tested under five different genetic models (co-dominant, dominant, co-dominant, recessive, and log-additive). Seven SNPs were associated with HAPE susceptibility. The rs41417552 SNP was associated with an increased risk of HAPE based on the results of the co-dominant (OR = 1.58; 95% CI = 1.04--2.40, *p* = 0.057 for the "A/G" genotype), dominant (OR = 1.62; 95% CI = 1.07--2.44, *p* = 0.022 for the "A/G-G/G" genotype), over-dominant (OR = 1.87; 95% CI = 1.06--3.27, *p* = 0.03 for the "A/G" genotype), and log-additive (OR = 1.59; 95% CI = 1.09--2.32, *p* = 0.017) models. The rs10984811 SNP increased HAPE risk in both the co-dominant (OR = 3.95; 95% CI = 1.33--11.73, *p* = 0.032 for the "C/C" genotype) and recessive (OR= 3.97; 95% CI = 1.34--11.75, *p* = 0.0089 for the "C/C" genotype) models. The rs17777329 SNP was also associated with an increased risk of HAPE in the co-dominant (OR = 1.88; 95% CI = 1.07--3.30, *p* = 0.051), dominant (OR = 1.95; 95% CI = 1.12--3.37, *p* = 0.018), over-dominant (OR = 1.87; 95% CI = 1.06--3.27, *p* = 0.03), and log-additive (OR = 1.89; 95% CI = 1.13--3.16, *p* = 0.015) models. The rs1075355 SNP was associated with increased HAPE risk in the co-dominant (OR = 1.65; 95% CI = 1.04--2.62, *p* = 0.093) and over-dominant (OR = 1.66; 95% CI = 1.04--2.63, *p* = 0.032) models. Additionally, the rs12226072 (OR = 0.58; 95% CI = 0.40--0.86, *p* = 0.0053) and rs6074799 (OR = 0.59; 95% CI = 0.37--0.93, *p* = 0.02) SNPs were associated with a decreased risk of HAPE in the over-dominant model, and the rs7677143 SNP was associated with a decreased risk of HAPE in the log-additive model (OR = 0.69; 95% CI = 0.48--0.99, *p* = 0.039) (Table [4](#T4){ref-type="table"}).

###### Logistic regression analysis of the associations between SNPs and HAPE risk

  SNP          Model           Genotype      Controls      Cases                    OR (95 % CI)^a^         *P*-value^a^   AIC     BIC
  ------------ --------------- ------------- ------------- ------------------------ ----------------------- -------------- ------- -------
  rs7677143    Co-dominant     T/T           199 (65.5%)   145 (72.9%)              1                       0.11           661.6   682.7
               T/C             94 (30.9%)    51 (25.6%)    0.72 (0.48--1.09)                                                       
               C/C             11 (3.6%)     3 (1.5%)      0.38 (0.10--1.40)                                                       
               Dominant        T/T           199 (65.5%)   145 (72.9%)              1                       0.062          660.6   677.5
               T/C-C/C         105 (34.5%)   54 (27.1%)    0.69 (0.46--1.02)                                                       
               Recessive       T/T-T/C       293 (96.4%)   196 (98.5%)              1                       0.16           662.1   678.9
               C/C             11 (3.6%)     3 (1.5%)      0.41 (0.11--1.53)                                                       
               Over-dominant   T/T-C/C       210 (69.1%)   148 (74.4%)              1                       0.16           662.1   678.9
               T/C             94 (30.9%)    51 (25.6%)    0.75 (0.50--1.12)                                                       
               Log-additive    ---           ---           ---                      **0.69 (0.48--0.99)**   0.039          659.8   676.7
  rs12226072   Co-dominant     T/T           131 (43.1%)   103 (51.8%)              1                       0.017          657.9   679
               A/T             139 (45.7%)   66 (33.2%)    **0.61 (0.41--0.90)**                                                   
               A/A             34 (11.2%)    30 (15.1%)    1.19 (0.67--2.09)                                                       
               Dominant        T/T           131 (43.1%)   103 (51.8%)              1                       0.077          660.9   677.8
               A/T-A/A         173 (56.9%)   96 (48.2%)    0.72 (0.50--1.04)                                                       
               Recessive       T/T-A/T       270 (88.8%)   169 (84.9%)              1                       0.16           662     678.9
               A/A             34 (11.2%)    30 (15.1%)    1.48 (0.86--2.54)                                                       
               Over-dominant   T/T-A/A       165 (54.3%)   133 (66.8%)              1                       0.0053         656.3   673.2
               A/T             139 (45.7%)   66 (33.2%)    **0.58 (0.40--0.86)**                                                   
               Log-additive    ---           ---           ---                      0.92 (0.71--1.20)       0.56           663.7   680.6
  rs6074799    Co-dominant     C/C           222 (73%)     159 (79.9%)              1                       0.03           659     680.1
               C/G             79 (26%)      35 (17.6%)    **0.60 (0.38--0.95)**                                                   
               G/G             3 (1%)        5 (2.5%)      2.57 (0.59--11.13)                                                      
               Dominant        C/C           222 (73%)     159 (79.9%)              1                       0.068          660.7   677.6
               C/G-G/G         82 (27%)      40 (20.1%)    0.67 (0.43--1.04)                                                       
               Recessive       C/C-C/G       301 (99%)     194 (97.5%)              1                       0.15           662     678.9
               G/G             3 (1%)        5 (2.5%)      2.88 (0.67--12.40)                                                      
               Over-dominant   C/C-G/G       225 (74%)     164 (82.4%)              1                       0.02           658.7   675.6
               C/G             79 (26%)      35 (17.6%)    **0.59 (0.37--0.93)**                                                   
               Log-additive    ---           ---           ---                      0.78 (0.52--1.15)       0.21           662.5   679.4
  rs41417552   Co-dominant     A/A           230 (75.7%)   135 (68.2%)              1                       0.057          658.3   679.4
               A/G             71 (23.4%)    59 (29.8%)    **1.58 (1.04--2.40)**                                                   
               G/G             3 (1%)        4 (2%)        2.68 (0.58--12.38)                                                      
               Dominant        A/A           230 (75.7%)   135 (68.2%)              1                       0.022          656.7   673.6
               A/G-G/G         74 (24.3%)    63 (31.8%)    **1.62 (1.07--2.44)**                                                   
               Recessive       A/A-A/G       301 (99%)     194 (98%)                1                       0.27           660.8   677.7
               G/G             3 (1%)        4 (2%)        2.35 (0.51--10.80)                                                      
               Over-dominant   A/A-G/G       233 (76.6%)   139 (70.2%)              1                       0.042          657.9   674.8
               A/G             71 (23.4%)    59 (29.8%)    **1.54 (1.02--2.34)**                                                   
               Log-additive    ---           ---           ---                      **1.59 (1.09--2.32)**   0.017          656.3   673.2
  rs10984811   Co-dominant     A/A           219 (72%)     139 (69.8%)              1                       0.032          659.2   680.3
               C/A             80 (26.3%)    49 (24.6%)    0.97 (0.64--1.49)                                                       
               C/C             5 (1.6%)      11 (5.5%)     **3.95 (1.33--11.73)**                                                  
               Dominant        A/A           219 (72%)     139 (69.8%)              1                       0.52           663.7   680.5
               C/A-C/C         85 (28%)      60 (30.1%)    1.14 (0.76--1.70)                                                       
               Recessive       A/A-C/A       299 (98.4%)   188 (94.5%)              1                       0.0089         657.2   674.1
               C/C             5 (1.6%)      11 (5.5%)     **3.97 (1.34--11.75)**                                                  
               Over-dominant   A/A-C/C       224 (73.7%)   150 (75.4%)              1                       0.68           663.9   680.8
               C/A             80 (26.3%)    49 (24.6%)    0.92 (0.60--1.39)                                                       
               Log-additive    ---           ---           ---                      1.28 (0.91--1.80)       0.16           662     678.9
  rs17777329   Co-dominant     A/A           275 (90.5%)   167 (83.9%)              1                       0.051          660.1   681.2
               A/G             28 (9.2%)     30 (15.1%)    **1.88 (1.07--3.30)**                                                   
               G/G             1 (0.3%)      2 (1%)        3.69 (0.33--41.57)                                                      
               Dominant        A/A           275 (90.5%)   167 (83.9%)              1                       0.018          658.4   675.3
               A/G-G/G         29 (9.5%)     32 (16.1%)    **1.95 (1.12--3.37)**                                                   
               Recessive       A/A-A/G       303 (99.7%)   197 (99%)                1                       0.3            663     679.9
               G/G             1 (0.3%)      2 (1%)        3.40 (0.30--38.26)                                                      
               Over-dominant   A/A-G/G       276 (90.8%)   169 (84.9%)              1                       0.03           659.3   676.2
               A/G             28 (9.2%)     30 (15.1%)    **1.87 (1.06--3.27)**                                                   
               Log-additive    ---           ---           ---                      **1.89 (1.13--3.16)**   0.015          658.1   675
  rs1075355    Co-dominant     G/G           253 (83.2%)   149 (74.9%)              1                       0.093          661.3   682.4
               G/C             46 (15.1%)    48 (24.1%)    **1.65 (1.04--2.62)**                                                   
               C/C             5 (1.6%)      2 (1%)        0.71 (0.13--3.85)                                                       
               Dominant        G/G           253 (83.2%)   149 (74.9%)              1                       0.052          660.3   677.2
               G/C-C/C         51 (16.8%)    50 (25.1%)    1.56 (1.00--2.45)                                                       
               Recessive       G/G-G/C       299 (98.4%)   197 (99%)                1                       0.6            663.8   680.7
               C/C             5 (1.6%)      2 (1%)        0.64 (0.12--3.51)                                                       
               Over-dominant   G/G-C/C       258 (84.9%)   151 (75.9%)              1                       0.032          659.5   676.4
               G/C             46 (15.1%)    48 (24.1%)    **1.66 (1.04--2.63)**                                                   
               Log-additive    ---           ---           ---                      1.40 (0.93--2.11)       0.1            661.4   678.3

Notes: ^a^Adjusted for age and sex. \**P*-value ≤ 0.05 indicates statistical significance.

Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; AIC, Akaike\'s Information Criterion; BIC, Bayesian Information Criterion.

To identify genes that might be involved in HAPE invasion, we also performed gene annotation and functional classification for the 7 significant loci we identified in the replication study. GO and KEGG pathway enrichment analyses identified 5 potential candidate genes located within ± 500kb of these SNPs (Table [5](#T5){ref-type="table"}). These genes were mainly involved in cellular tight junctions, oxidation and reduction, extracellular matrix metabolism, pulmonary development, and pulmonary smooth muscular tension adjustment.

###### Go and pathway analysis of the top genes of GWAS

  ------------------------------------------------------------------------------------ --------------- ------------------------ ------------------
  **Function**                                                                         ***p*-value**   **Adjusted *p*-value**   **Genes**
  zinc ion binding                                                                     7.99E-07        1.60E-06                 *ADAMTS18;VAT1L*
  protein binding                                                                      1.59E-05        1.06E-05                 *INADL;KCNV2*
  thyroxine 5-deiodinase activity                                                      7.56E-05        3.36E-05                 *DIO3*
  very-low-density lipoprotein receptor activity                                       2.27E-04        6.52E-05                 *VLDLR*
  thyroxine 5′-deiodinase activity                                                     2.27E-04        6.52E-05                 *DIO3*
  metal ion binding                                                                    2.45E-04        6.52E-05                 *ADAMTS18*
  low density lipoprotein receptor activity                                            8.31E-04        1.45E-04                 *VLDLR*
  peptidase activity                                                                   8.69E-04        1.45E-04                 *ADAMTS18*
  oxidoreductase activity                                                              0.001153        1.58E-04                 *WWOX*
  selenium binding                                                                     0.002265        2.01E-04                 *DIO3*
  ATP binding                                                                          0.004538        3.70E-04                 *CCT5*
  voltage-gated potassium channel activity                                             0.007231        5.26E-04                 *KCNV2*
  metalloendopeptidase activity                                                        0.007756        5.35E-04                 *ADAMTS18*
  unfolded protein binding                                                             0.008356        5.52E-04                 *CCT5*
  potassium ion binding                                                                0.00948         6.12E-04                 *KCNV2*
  nucleotide binding                                                                   0.010312        6.34E-04                 *CCT5*
  manganese ion binding                                                                0.011276        6.63E-04                 *NUDT7*
  coenzyme binding                                                                     0.0115          6.67E-04                 *WWOX*
  hydrolase activity                                                                   0.012359        6.83E-04                 *NUDT7*
  voltage-gated ion channel activity                                                   0.013964        7.35E-04                 *KCNV2*
  protein dimerization activity                                                        0.031265        0.001374                 *WWOX*
  magnesium ion binding                                                                0.032144        0.001398                 *NUDT7*
  hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides   0.053236        0.002117                 *NUDT7*
  calcium ion binding                                                                  0.06698         0.002528                 *VLDLR*
  receptor activity                                                                    0.121001        0.00436                  *VLDLR*
  **Pathways**                                                                         ***p*-value**   **Adjusted *p*-value**   **Genes**
  1,4-Dichlorobenzene degradation                                                      0.000371        0.000742                 CMBL
  gamma-Hexachlorocyclohexane degradation                                              0.006661        0.001665                 CMBL
  Maturity onset diabetes of the young                                                 0.008871        0.001971                 IAPP
  Tight junction                                                                       0.049301        0.002641                 INADL
  Wnt signaling pathway                                                                0.054948        0.002641                 PPP2R5C
  ------------------------------------------------------------------------------------ --------------- ------------------------ ------------------

DISCUSSION {#s3}
==========

In this study, we conducted a two-stage GWAS analysis to investigate the genetic factors associated with HAPE in a Han Chinese population. Seven loci, including four susceptibility loci and three protective loci, were found to be associated with HAPE in this analysis. Gene annotation and functional classification of these loci revealed that five of the candidate genes are potentially involved in the pathogenesis of HAPE. To the best of our knowledge, this is one of the largest studies to explore the genetic factors underlying the development of HAPE in a Han Chinese population.

The rs10789097 locus contained no annotated genes, and the gene nearest to it was INADL, which encodes inactivation no-after potential (INAD) protein, also known as protein associated with Lin seven 1 (Pals1) -associated tight junction protein (PATJ). INAD contains multiple PDZ domains, which are protein-protein interaction modules that typically bind to short peptide sequences at the carboxyl terminus of target proteins. Proteins containing multiple PDZ domains often bind to different transmembrane and intracellular proteins and play central roles as organizers of multimeric complexes \[[@R15]\]. PATJ is a polarity protein and plays a complex role in the maintenance of epithelial polarity \[[@R16]\]. Considering that stress failure in pulmonary capillaries is an important contributor to HAPE pathogenesis, we speculate that the INADL gene may also impact the pathogenesis of HAPE.

The KCNV2 gene, which encodes the Kcnv2 protein, belongs to a group of potassium channel modulatory subunits that are electrically silent and cannot form functional homotetramers. These silent subunits form heterotetramers that modulate the properties of other subunits, increasing the functional diversity of channel subfamilies \[[@R17]\]. Voltage-gated K^+^ (K~V~) channel activity in pulmonary artery smooth muscle cells (PASMC) is important for the control of apoptosis and proliferation as well as the regulation of membrane potential and pulmonary vascular tone \[[@R18]\]. A previous study demonstrated that KNCV2 contributes to susceptibility to and was considered a genetic modifier of epilepsy \[[@R17]\]. However, the role of KNCV2 in HAPE remains unknown, and additional studies are needed.

The rs1075355 SNP had the strongest association in this study. It is located in the intron of the VAT1L gene and encodes a vesicle amine transport 1 homologue; its cellular localization and functions have not yet been researched. An association study suggested that a locus on chromosome 16q23-24 (including VAT1L) affected HDLC levels in two independent French-Canadian populations \[[@R19]\]. Additionally, a genome-wide association study of the rate of cognitive decline in Alzheimer\'s disease indicated that rs9934540 genetic variants in the VAT1L gene intron were positively associated with the development of Alzheimer\'s disease \[[@R20]\]. Two different genes, ADAMTS18 and WWOX, are adjacent to the rs1075355 SNP.

ADAMTS18 is a member of the ADAMTS protease family, which is comprised of complex secreted enzymes containing a reprolysin-type prometalloprotease domain attached to an ancillary domain with a highly-conserved structure including at least one thrombospondin type 1 repeat. Known functions of ADAMTS proteases include processing procollagens and von Willebrand factor and catabolism of aggrecan, versican, and brevican. ADAMTS also play important roles in connective tissue organization, coagulation, inflammation, arthritis, angiogenesis, and cell migration \[[@R21], [@R22]\] and are regulated by the Tissue Inhibitor of Metalloproteinase 3 Gene (TIMP3). Furthermore, Kobayashi *et al*.\'s study in a Japanese population demonstrated that TIMP3 was associated with susceptibility to HAPE \[[@R23]\]. TIMPs play a crucial role in the physiological turnover of the extracellular matrix (ECM) by tightly regulating matrix metalloproteinase (MMP) activity \[[@R24]\]. TIMP3 is the only TIMP that binds tightly to the ECM, and the balance between MMPs and TIMPs plays an important role in maintaining the integrity of healthy tissues. Disturbances of the TIMP/MMP system are implicated in various pathologic conditions in lungs, including pulmonary inflammation, edema, emphysema, and fibrosis, where loss of ECM integrity is a principal feature \[[@R25]\]. Our findings together with those of previous studies demonstrate that the balance between MMPs and TIMPs plays an important role in HAPE pathogenesis.

The human WWOX gene encodes a putative tumor suppressor WW domain-containing oxidoreductase WOX1 (also known as WWOX or FOR). High frequencies of loss of heterozygosity (LOH) in this gene have been observed in prostate, lung, breast, and other cancers \[[@R27]\]. A recent genome-wide association analysis identified WWOX as one of the loci associated with forced vital capacity (FVC), a spirometric measure of pulmonary function used to diagnose and monitor lung diseases \[[@R27]\]. These findings indicate that the WWOX gene may be involved in lung development and the pathogenesis of restrictive lung disease; future studies are needed to determine whether WWOX is similarly associated with HAPE pathogenesis.

Although the statistical power of the present study was sufficient, some limitations should be considered when interpreting these results. First, the patient sample sizes were relatively small, and the association between the identified polymorphisms and HAPE susceptibility should be confirmed in future studies with larger sample sizes. Secondly, the mechanisms by which the potential candidate genes contribute to the pathogenesis of HAPE remain unclear, and functional studies of these candidate genes are needed. In conclusion, our study provides new evidence regarding the pathogenesis of HAPE in the Han Chinese population. Although the genetic factors that contribute to the development of HAPE remain largely unknown, we identified candidate genes that contribute to HAPE susceptibility. However, polymorphisms in these genes should be examined further before definitive conclusions regarding their role in HAPE pathogenesis can be made.

MATERIALS AND METHODS {#s4}
=====================

Study populations {#s4_1}
-----------------

In this two-stage case-control study, we evaluated associations between genetic variants across the human genome and the risk of HAPE. All participants included in the study were from the Han Chinese population. Study subjects for both GWAS scan of HAPE and the replication phase of the experiment were selected according to detailed inclusion and exclusion criteria. Briefly, patients who lived on the Tibet Plateau and were diagnosed with HAPE were recruited from the General Hospital of Tibet Military Region. Control subjects were Han Chinese immigrants living in Lhasa, Tibet, and their medical histories and physical examinations confirmed that they were in good health. Demographic information was collected through interviews using a standard questionnaire. Ultimately, 267 HAPE cases (89 recurrent HAPE cases; mean age 32.6 ± 10.7 years) and 304 controls (mean age 36.2 ± 4.5 years) were selected for the study. Two mL of venous blood were collected from each individual into tubes containing 2% EDTA-K2, centrifuged, and stored at --80°C until analysis. DNA was extracted from whole blood samples using the QIAamp^®^ DNA Blood Mini kit (Qiagen), and DNA concentrations were measured using a NanoDrop 2000. Informed consent was obtained from all subjects, and the Human Ethics Committee of our institute approved the investigation.

Study design {#s4_2}
------------

For the GWAS scan experiment, we scanned DNA samples from 68 patients with recurrent HAPE using Affymetrix SNP Array 6.0 Chips. The allele frequencies of the 68 patients were then compared to those of 84 HapMap CHB subjects to identify significant differences in SNP frequencies. In the replication experiment, associations between the SNPs identified in the GWAS scan and risk of HAPE where examined in 199 HAPE patients and 304 unrelated healthy controls. Furthermore, to identify candidate genes that might underlie HAPE susceptibility, we conducted Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for the genes involved in the associated genetic loci.

Quality control (QC) in GWAS {#s4_3}
----------------------------

A total of 906,660 SNPs were genotyped in 68 patients with recurrent HAPE during the GWAS experiment using Affymetrix Genome-Wide Human SNP Array 6.0 Chips as described previously \[[@R28]\]. A systematic quality control (QC) procedure was applied to both SNPs and samples prior to the association analysis. SNPs were excluded if they (i) did not map onto autosomal chromosomes; (ii) had a call rate of less than 95%; (iii) had a minor allele frequency (MAF) less than 0.05; or (iv) deviated from Hardy-Weinberg equilibrium (*p* \< 0.001). Sixty-eight HAPE cases and 84 controls with 502,689 SNPs remained after QC.

SNP selection and genotyping in the replication study {#s4_4}
-----------------------------------------------------

After genome-wide association analysis, we compared the allele frequencies of the 502,689 SNPs in the 68 recurrent HAPE cases to those in the 84 HapMap CHB controls using a chi-squared (χ^2^) test. Allele frequencies differed significantly between HAPE cases and controls for 77 SNPs. In the replication study, these 77 SNPs were genotyped in 199 HAPE patients and 304 normal controls. SNPs that were significantly associated with HAPE risk (*p* \< 0.05) in the replication study were selected for GO and KEGG pathway enrichment analyses. Genotyping was performed using Sequenom MassARRAY Assay Design 3.0 Software \[[@R29]\] with a genotype success rate greater than 97.3%.

Statistical analysis {#s4_5}
--------------------

SPSS 17.0 statistical software was used for statistical analysis. An exact test was used to test the departure of each SNP frequency from Hardy--Weinberg equilibrium (HWE) in control subjects. Differences in SNP genotype distribution between HAPE patients and controls were compared using a χ^2^ test \[[@R30]\]. Odds ratios (ORs) and 95% confidence intervals (CIs) were determined using unconditional logistic regression analysis with adjustments for age and gender \[[@R31]\]. All *p* values presented in this study are two-sided; *p* \< 0.05 indicated a statistically significant difference.

Associations between SNPs and HAPE risk were tested using various genetic models (co-dominant, dominant, over-dominant, recessive, and log-additive) and analyzed using SNP Stats software (obtained from <http://bioinfo.iconcologia.net>, Catalan Institute of Oncology, Barcelona, Spain). To reduce population stratification, a multidimensional scaling approach (MDS) was used and a QQ-plot was generated using PLINK software (version 1.07) (<http://www.cog-genomics.org/plink2/>) \[[@R32]\]. R software (version 2.11.1) was used for statistical analysis and to generate plots, including Manhattan plots. GO analysis were performed using Bingo software \[[@R33]\], and pathway enrichment analyses were performed using Mas 3.0 software (<http://bioinfo.capitalbio.com/mas3/>).
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